manag chang gx
amneal report result follow downward revis ebitda
guidanc juli guidanc cut support stanc gener ew
continu reinforc cautiou stanc us gx addit paul bisaro former
exec chairman rob stewart former ceo resign respect
posit amneal founder chirag chintu patel assum co-ceo role
ow-rat stock gener space except ow
despit gx exposur remain ew lower pt
new management focu oper effici nt revamp segment lt
new co-ceo gave high-level strateg vision note detail
come plan center around drive nt oper effici
cost ration suppli chain manag addit invest behind
complex gx specialti product manag call grow hospital-bas
steril inject franchis develop biosimilar diversifi
bd opportun medium longer term object
review revenu vs ep vs came
consensu top-line weak softer gx sale y/i
see continu competit gaggrenox yuvafem gvoltaren profit
impact lower gm within gx vs estim due product sale mix
higher penalti failur suppli underutil plant capac inventori
obsolesc charg manag expect gm improv throughout
valuat valu amneal use ev/ebitda multipl discount
histor mean yield pt upsid risk improv
gx price posit clinic data faster de-lever downsid risk
worsen gx environ failur faster declin specialti
sale doj price fix case result materi fine upcom catalyst gnuvar
launch late phase readout patient pd
quarterli annual ep usd
lower usd
return equiti ttm
link barclay live interact chart
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
equal weight despit one top gener
growth outlook coverag remain
sidelin due difficult gener environ
worsen gener environ
failur faster declin specialti portfolio sale doj
price fix case result materi fine
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
gx top-lin weak
lower gm drove
under-perform versu
barclay research estim compani data refinitiv data except per share amount
follow downward revis ebitda guid juli manag updat
guidanc metric addit expect fy ebitda rang
highlight amrx current guidanc rel origin guidanc provid
ebitda guidanc lower
updat guidanc
metric report
 vs consvari vs gross total sg total madjust effect tax mdilut share barclay amneal pharmaceut
balaji prasad md herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
